Search Medical Condition
Please enter condition
Please choose location from dropdown

Gijon, Spain Clinical Trials

A listing of Gijon, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (12) clinical trials

GEM-CLARIDEX: Ld vs BiRd

BiRd Arm Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles. Dosing is as follows: Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle. If a dose of clarithromycin is missed, it should be taken as soon as possible on the ...

Phase

0.0 miles

Learn More »

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »

International Breast Cancer Biomarker Standard of Care and Real World Outcomes Study

Background/Rationale: Within the setting of metastatic human epidermal growth factor receptor 2 negative (HER2-ve) breast cancer limited epidemiological data exist on the prevalence of pathogenic mutations of breast cancer susceptibility gene (BRCA) and other homologous recombination repair (HRR) genes. There are also limited data on the treatments and clinical outcomes ...

Phase N/A

0.0 miles

Learn More »

Firazyr Patient Registry Protocol (Icatibant Outcome Survey - IOS)

The Firazyr Patient Registry is a multicenter, prospective, observational study for patients treated with Firazyr in countries where it is currently approved. The entry of patients into the Firazyr Registry is at the discretion of the physician and the patient and is not a pre-requisite for prescribing Firazyr.

Phase N/A

0.6 miles

Learn More »

Dimethyl Fumarate (DMF) Observational Study

Patients aged 12 to under 18 may be included where enrollment of pediatric patients in this study is considered observational and is permissible by local regulations.

Phase N/A

0.7 miles

Learn More »

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure

The purpose of this randomized, actively controlled, double-blind study is to demonstrate the superiority of sacubitril/valsartan over enalapril in increasing non-sedentary physical activity chronic heart failure patients with reduced ejection fraction. Physical activity will be continuously measured by means of a wrist-worn accelerometry device from 2 weeks before until 12 ...

Phase

2.8 miles

Learn More »

To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients

The purpose of the protocol, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed

Phase N/A

3.35 miles

Learn More »

Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours

The purpose of this study is to evaluate the utility of the QLQ-GINET21 in making clinical and therapeutic decisions.

Phase N/A

3.35 miles

Learn More »

Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment

Prospective, multicentre, observational study in patients with metastatic renal cell carcinoma (mRCC) receiving a tyrosine kinase inhibitor as first-line treatment according to routine clinical practice, designed to evaluate the incidence of fatigue and hand-foot syndrome in order to determine how these affect the baseline characteristics of the patient and his/her ...

Phase N/A

3.35 miles

Learn More »

A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Phase N/A

3.35 miles

Learn More »